Lee Kang-In, Lee Seo-Young, Hwang Dong-Youn
Department of Biomedical Sciences, CHA University, Seongnam, Gyeonggi-do, Republic of Korea.
Stem Cells Int. 2016;2016:6853081. doi: 10.1155/2016/6853081. Epub 2016 Jan 12.
Human induced pluripotent stem cells (iPS cells) hold great promise in the field of regenerative medicine, especially immune-compatible cell therapy. The most important safety-related issues that must be resolved before the clinical use of iPS cells include the generation of "footprint-free" and "xeno-free" iPS cells. In this study, we sought to examine whether an extracellular matrix- (ECM-) based xeno-free culture system that we recently established could be used together with a microRNA-enhanced mRNA reprogramming method for the generation of clinically safe iPS cells. The notable features of this method are the use of a xeno-free/feeder-free culture system for the generation and expansion of iPS cells rather than the conventional labor-intensive culture systems using human feeder cells or human feeder-conditioned medium and the enhancement of mRNA-mediated reprogramming via the delivery of microRNAs. Strikingly, we observed the early appearance of iPS cell colonies (11 days), substantial reprogramming efficiency (0.2-0.3%), and a high percentage of ESC-like colonies among the total colonies (~87.5%), indicating enhanced kinetics and reprogramming efficiency. Therefore, the combined method established in this study provides a valuable platform for the generation and expansion of clinically safe (i.e., integration- and xeno-free) iPS cells, facilitating immune-matched cell therapy in the near future.
人诱导多能干细胞(iPS细胞)在再生医学领域,尤其是免疫相容性细胞治疗方面具有巨大的应用前景。在iPS细胞临床应用之前必须解决的最重要的安全相关问题包括生成“无足迹”和“无异源”的iPS细胞。在本研究中,我们试图检验我们最近建立的基于细胞外基质(ECM)的无异源培养系统是否可以与微小RNA增强的mRNA重编程方法一起用于生成临床安全的iPS细胞。该方法的显著特点是使用无异源/无饲养层培养系统来生成和扩增iPS细胞,而不是使用人类饲养细胞或人类饲养细胞条件培养基的传统劳动密集型培养系统,并且通过微小RNA的递送增强mRNA介导的重编程。令人惊讶的是,我们观察到iPS细胞集落的早期出现(约11天)、显著的重编程效率(约0.2 - 0.3%)以及总集落中高比例的胚胎干细胞样集落(约87.5%),表明动力学和重编程效率得到了提高。因此,本研究中建立的联合方法为生成和扩增临床安全(即无整合和无异源)的iPS细胞提供了一个有价值的平台,有助于在不久的将来实现免疫匹配的细胞治疗。